Abstract To assess whether quantitative visual scoring (QVS) is a better early predictor of progression-free survival (PFS) in patients on chemotherapy for metastatic melanoma using CT than the currently used Response Evaluation Criteria in Solid Tumors (RECIST) standard. Retrospective evaluation of 65 consecutive patients with metastatic melanoma on treatment who had a baseline and follow-up CT after two cycles of therapy. QVS was used to code imaging findings on the radiology reports considering size change, brain metastases, new lesions, mixed lesion response, and the number of organ systems involved. RECIST 1.1 criteria placed patients in the progressive disease, stable disease, or partial response groups. Multiple regression analysis was used to correlate the various independent variables with PFS. The Cox hazard proportions ratio, median survival, and Kaplan-Meier curves of the different prognostic groups were calculated. QVS of size change was found more sensitive in detecting patients deteriorating (57.1% versus 37.5%) or improving (23.8% versus 10.7%), more correlated with the median PFS for the deteriorating (1.8 versus 1.7 months), stable (5.6 versus 4.0 month), and improving (8.3 versus 5.5 months) categories and more predictive of PFS (Cox hazard proportion ratio of 3.070 versus 1.860) than RECIST 1.1 categorization. Multiple regression analysis demonstrated QVS of lesion size correlated most closely with PFS among the variables assessed (r=0.519, p<0.0001). QVS in this study was superior to standard RECIST categorization in terms of discriminating treated metastatic melanoma patients likely to have longer PFS.
Introduction
Little work has been undertaken to validate imaging as a surrogate endpoint for patient clinical responses to the many new cancer therapies in development. Most prior work has been directed at measuring lesion size on CT using the Response Evaluation Criteria in Solid Tumors (RECIST) [1, 2] . Unidimensional RECIST size measurements have been found to be relatively poor estimates of volume, particularly in lesions with complex shapes [3] and are restricted to a small subset of defined target lesions. In addition, even the most recent update of RECIST (version 1.1) only assesses changes in lesion size, rather than incorporating consideration of the many other findings evident in modern imaging studies [2] . This greatly restricts full exploitation of both conventional and emerging modalities.
Our objective in this project was to develop and test a quantitative visual scoring (QVS) system, exploiting the full range of imaging parameters in assessing cancer treatment response. For this, we selected a set of patients with metastatic melanoma receiving either nanoparticle albumin-encapsulated (nab-)paclitaxel, a new chemotherapy agent for this condition, or dacarbazine (DTIC), the standard agent for this condition.
Survival in melanoma patients with classical therapy is of relatively short duration with median overall survival times of 6-9 months and median progression-free survival (PFS) of about 2 months [4] . These outcomes have not been altered despite decades of therapeutic development.
While some recent progress has been made in metastatic melanoma management, validation of new means of imaging assessment remains a priority. RECIST defined response rates do not necessarily correlate with outcome and survival [5] . We undertook the present study to evaluate whether a new systematic, imaging interpretation paradigm, QVS, could perform better than conventional RECIST scoring in assessing patient outcomes in metastatic melanoma.
Methods
This retrospective evaluation was in accord with the principles of the Health Insurance Portability and Accountability Act and was approved by the University of Arizona's Human Subjects Protection Program. Informed consent was not required because there was no impact on patient care. Information was obtained from the radiology and clinical information systems. The records of all consecutive melanoma patients treated with either DTIC or nab-paclitaxel (Abraxane; Celgene, Summit, New Jersey, USA) at our institution from 2004 to 2009 were searched. The study group only included patients having at least a baseline and follow-up body CT (relevant anatomic regions included) after two cycles of chemotherapy (6-8 weeks) . Other clinical parameters extracted from the patient records included their age, gender, serum lactic dehydrogenase (LDH) baseline, and completion of therapy levels as a comparative serologic marker of tumor response [6] , date and reason of therapy discontinuation, time of last known contact with the patient, and date of death, if relevant (Table 1) .
A simplified QVS scheme was used to code imaging findings on the radiology reports, if newly apparent on the follow-up CT scan as present or absent and, if apparent on the baseline and follow-up scans, as increased, no change, or decreased, considering all neoplastic lesions ( Table 2 ). The tumor burden was quantified by recording the number of organ systems involved. Brain metastases were documented and coded as present (score of 1) or absent (score of 0) on either the baseline or follow-up head CT or MRI examinations. RECIST 1.1 criteria [2] were used to calculate the percentage difference in the sum of the diameters of up to five target lesions on the baseline and follow-up imaging studies. Patients were placed in the RECIST categories of progressive disease (PD), stable disease (SD), or partial response (PR) based on these percentage changes from baseline. No patients had a complete response. One or more new lesions categorized patients automatically as PD (Table 3) . If parameters could not be determined from the reports, they were defined as indeterminate. All imaging parameters, either QVS or RECIST based, were coded using the reports from the baseline and first follow-up body CT scans by a single board-certified radiologist who was blinded to all clinical information other than that the patients were treated for metastatic melanoma.
PFS was defined as beginning when the therapy under evaluation was started and ending when disease progression was documented. Overall survival (OS) was defined as beginning when the therapy under evaluation was started and ending at the time of documented death or last contact. If both nab-paclitaxel and DTIC were used at different times to treat an individual patient, then the last of the two therapies 
Results
QVS of overall lesion size change was the single best correlated imaging parameter with PFS and OS, although still demonstrating only fair corresponding regression coefficients of 0.519 (p<0.0001) and 0.375 (p=0.0021), respectively. The resulting correlation coefficients improved to 0.541 (p=0.0148) for PFS and 0.499 (p=0.0380) for OS when combining QVS of overall lesion size change with other parameters including the presence or absence of new lesions, brain metastases, mixed lesion response, number of organ systems involved with metastases, and serum LDH levels. Replacing QVS of overall lesion size change with RECIST size change categorization, placing patients into traditional PD (≥20% summed target lesion diameter increase), PR (≥30% summed target lesion diameter decrease), and SD (all other summed percent target lesion diameters), resulted in deterioration in correlation with PFS to 0.412 (p=0.3988) and OS to 0.394 (p=0.4426). The relatively wide RECIST 1.1 SD category for the overall percentage change in the summed target lesion diameters resulted in the scoring system placing most patients in the no change or SD category. QVS assessment of overall tumor lesion size change between scans resulted in 16/65 (24.6%) versus 6/58 (10.3%) patients placed in the improving category, 12/65 (18.5%) versus 30/58 (51.7%) patients placed in the no change category, and 37/65 (56.9%) versus 22/58 (37.9%) patients placed in the deteriorating category compared with RECIST 1.1 size assessment using standard categorical boundaries of≥20% increase or 30% decrease in target lesion diameters between scans.
QVS assessment of overall lesion size change demonstrated superior prediction of median survival differences between the three prognostic groups for either PFS or OS compared with RECIST 1.1 size assessment alone using standard categorical boundaries for PR and PD (Tables 4  and 5 ). The Cox hazard ratios for predicting both PFS and OS were also superior for QVS of overall lesion size change between scans compared with standard RECIST 1.1 assessment of target lesion size change using standard categorical boundaries. Reducing the RECIST 1.1 target lesion categorical boundaries to ≥10% decrease or increase to place patients in the PR or SD groups enhanced both sensitivity in detecting both improving and deteriorating patients on therapy and superior predictions of both PFS and OS compared with standard RECIST size change categorization (Tables 4 and 5 ).
Combining the presence or absence of new lesions with QVS size change assessment resulted in no change in patient categorization. New lesions were assumed to place patients in the deteriorating category regardless of the size change as defined currently by RECIST 1.1. RECIST 1.1 standard size change categorization was significantly altered when combined with the assessment of new lesions. The number of patients categorized as improving or deteriorating increased with resulting improvements in prediction of both median survival of the prognostic groups as well as the Cox hazard ratios for both PFS and OS. Despite these improvements, QVS assessment of overall lesion size change still demonstrated better sensitivity in placement of patients in the improving and deteriorating groups following treatment compared with RECIST 1.1. QVS also demonstrated enhanced prediction of PFS and equivalent prediction of OS compared with standard RECIST 1.1 categorization (size change combined with new lesion development) based on the median survival times of the resulting prognostic groups and corresponding Cox hazard ratios (Tables 4, 5 , and 7). Kaplan-Meier survival curves for the three prognostic groups determined by QVS of lesions size change alone demonstrated superior separation compared with standard RECIST 1.1 size change categorization. (Fig. 1a, b) . We evaluated a standard tumor marker for patient treatment response, the serum LDH level. We recorded the baseline, completion of therapy, and percent change in these values and found the best predictions of both PFS and OS resulted from completion of therapy LDH levels (Table 6 ) with the change in these levels having the worst predictive value for either PFS or OS (Table 7) . No improvement resulted from combining these levels with the individual or various combinations of imaging parameters in predicting PFS or OS. 
Discussion
RECIST the current standard has been found to be deficient to use in clinical trials to predict patient survival by oncologists, radiologists and pharmaceutical companies [7] . RECIST is limited to anatomic evaluation of lesion size change between scans [1, 2]. Many additional potentially useful prognostic imaging findings are therefore not incorporated. These have to date been investigated in limited studies, which have prevented them from being universally adopted due to lack of a statistically adequate number of patients to do so. Changes in tumor perfusion on both CT [8] and MR [9] , oxygenation and water diffusion by MRI [10] , and lesion morphology on CT [11] , have been compared with RECIST assessment and found in limited evaluations to improve prediction of survival. Survival, the gold standard in these evaluations, has varied with the Cox hazard proportions radio, median survival, and Kaplan-Meier survival curves used to compare the results from the different imaging scoring methods. Furthermore RECIST, even in evaluating size, the one imaging parameter the scoring system has been developed to address, has severe limitations in doing so. By definition, it is restricted to a limit of only five target lesions by the current version, RECIST 1.1 [2] . This restriction prevents its quantitative application to many other readily observable changing potentially relevant lesions in the assessment of tumor response. In addition, it uses only the single longest tumor dimension (other than for lymph nodes in which the short axis is measured) which has been found inadequate in reflecting tumor 3-D volume [3] . This shortcoming is exacerbated in lesions with complex shapes, ill defined borders, or areas of non-viable tumor [12] . Another RECIST limitation is that it prohibits use of lesions below a 1.0-cm diameter size threshold, which eliminates many readily evaluable lesions such as small lung nodules or other small organ metastases which clearly change between scans but cannot be used. Lesions between 5 mm and 1.0 cm in diameter are readily observed on current CT scanners.
RECIST uses categories of target lesion summed size change, which are broad, and have been found relatively insensitive to change [13] . This issue has become increasing more important with new therapies becoming available which the patient can be transitioned to which may improve survival, or reducing the need to continue with expensive, futile toxic therapies. Wide variability exists between different observers in applying even the simplified single diameter measurements required by RECIST 1.1 between observers at the same site and at multiple sites [14] .
The current project further developed a user-friendly visual scoring method (QVS) which incorporates a Likert-type scale [15, 16] , for scoring radiologists' observations of the interval development of new or changing imaging findings. Use of QVS exploits the large body of established work [17] [18] [19] [20] [21] [22] [23] from the scientific discipline of human perception. Previous investigators have found the use of QVS to quantify the vast array of perceived imaging findings identified in daily practice by imagers thereby extending the number of evaluable parameters beyond lesion size change, to which RECIST or volumetric analysis are restricted. Prior work has found QVS of the change in lesion size between scans to be often superior to the RECIST method in the consideration of lesions with complex shapes, large interfaces with adjacent normal structures (such as a pleural surface), or nodules too small to be considered measurable by RECIST [24] . Furthermore, QVS can more quickly and flexibly be adapted to incorporate new relevant imaging features, which may be important in predicting patient response and can more easily be introduced into the practice setting than the hardware and software upgrades required for techniques involved in computer aided diagnosis or 3-D lesion volumetric analysis [13, 24, 25] . We employed simplified Likert-type scoring scales to assess the presence or absence of an imaging finding (i.e., new lesion development) or the interval change in an imaging feature (i.e., size change) to relate quantitatively single or combined imaging findings to patient outcome (PFS or OS). Our analysis confirmed those of prior investigations coding human perception of size change of neoplastic lesions in that it was more sensitive to change in patient status on therapy and more predictive of their survival than the currently used RECIST scoring paradigm [24] [25] [26] . However it should be noted that imaging, was only slightly superior to a relatively inexpensive serum marker, the serum LDH level, in predicting patients likely to do well on therapy. Combining imaging and serologic parameters did not improve prediction of patient survival on treatment.
We envision a simplified scale, like the one we used, could be placed in structured reports and incorporated into radiology information systems if supported by vendors [27] . Radiologists could then quantitatively record the pattern based imaging features they see in their daily practices in structured reports using standardized terms, such as in the RadLex lexicon currently being developed by the RSNA [28] . The value of the imaging features recorded would be determined based on their reproducibility and accuracy in predicting patient outcomes, such as survival. A tumor registry could be developed assessing the accumulated QVS of a variety of imaging findings (size change as well as other features) recording both the scored imaging findings and the patient outcomes which they independently predict. Improvements would be necessary in linking the radiology information system with the remainder of the patient electronic medical record to allow this to occur however.
The current project was limited in that imaging interpretation data was extracted from the radiology reports by a single radiologist and not re-read to address reproducibility. However, three prior studies with two other metastatic cancers, colon and lung [24] [25] [26] , have demonstrated improved agreement between radiologists and physician assistants when re-reading cases using Likert-type scales to score imaging findings. The Likert-type scale used in this project was simpler than ones utilized previously and therefore less likely to be subject to inter or intraobserver disagreements. We believe our results are sufficiently promising to warrant subsequent testing, both extracting Fig. 1 a, b Kaplan-Meier survival curves plotting progression-free survival (Cum. Survival) against the number of months (horizontal axis). a QVS placement of patients into increasing, no change, and decreasing overall lesion size categories corresponding to patients deteriorating, stable, and improving on treatment. Differences in survival prediction between curves were statistically significant (p< 0.0001, log-rank test). b The RECIST 1.1 categorization based on target lesion size change alone without new lesions. PD progressive disease, SD stable disease, PR partial response. Differences in survival prediction between curves were statistically significant (p=0.0014, log-rank test). QVS demonstrates improved separation in categorizing patients compared to RECIST 1.1 target lesion size categorization particularly when comparing the patients deteriorating on treatment from the stable and improving categories information from radiology reports (possibly using natural language processing programs), or from having observers re-interpret the images to measure the reproducibility of QVS in multiple reader, multisite evaluations.
A relatively short survival tumor, metastatic melanoma, was used in the current investigation because the primary and secondary survival endpoints were short and therefore readily measurable. The survival times of patients with metastatic malignancies such as melanoma, colon, and lung are still very short despite active research in these areas [29] . New drugs are being rapidly brought into clinical trials and require early evaluation to promote quick development of potentially successful therapies and termination of therapies likely to be futile [30] [31] [32] [33] .
Our study population was relatively small and additional studies are required to establish QVS as a new tumor response scoring paradigm in a variety of metastatic cancers including melanoma and other types of cancers. QVS can be used not only to code CT findings but could be potentially expanded flexibly to incorporate visual-based features from other modalities such as MRI, positron emission tomography, ultrasound, and emerging modalities which have visualbased features requiring human interpretation. Current sizebased imaging parameters are only fair in predicting survival as measured in this study in metastatic melanoma patients and in other treated malignancies [25, 26] . QVS provides a methodology for scoring a variety of imaging findings which can be compared in how they predict patient outcomes with the current largely size-based anatomic parameters as a standard of reference. Visually apparent optical intensity changes coding tumor metabolic activity in response to therapy can be assessed by QVS in the same manner as was done with the size-based anatomic parameters in the current project.
In summary new therapies are currently being developed for metastatic cancer which need to be quickly evaluated for their impact on patient survival. QVS promises to enhance patient response categorization compared to RECIST 1.1, the current imaging surrogate endpoint used by the Food and Drug Administration to aid in the drug approval process and by pharmaceutical companies [33] . QVS in this project demonstrated superior discrimination compared with RECIST 1.1 in predicting patients likely to improve or deteriorate on treatment for metastatic melanoma early in the course of treatment. We believe our results justify incorporating QVS in other larger retrospective and prospective studies utilizing CT and other modalities to assess early tumor therapy response.
